Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| J. Sorensen | M | 67 |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 20 years |
| Chris Degnan | M | 44 | 5 years | |
| Jennifer Stacey | F | 59 | 3 years | |
| Patrick O'Neil | M | 50 | 23 years | |
| Michael Powell | M | 69 | 8 years | |
| Elizabeth Hougen | F | 62 | 24 years | |
| Kevin Lokay | M | 67 | 5 years | |
| Spencer R. Berthelsen | M | 71 | 22 years | |
| Linda West | F | 64 | 4 years | |
| Lawrence Alleva | M | 74 | 5 years | |
| Emmett Cunningham | M | 63 | 6 years | |
| Sanjay Bhanot | M | - | 24 years | |
| Andie Collier | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joel F. Sussman | M | 75 | - | |
| Campbell Murray | M | 48 | 7 years | |
| Dan Kisner | M | 77 | 8 years | |
| Jason Fuller | M | 46 | - | |
| Thomas Dyrberg | M | 69 | - | |
| Frederick Muto | M | 70 | 21 years | |
| John Reed | M | 65 | 11 years | |
| Arthur Fratamico | M | 58 | - | |
| Lance Leopold | M | - |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | - |
| Ming Guo | M | 67 |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 5 years |
| Ethel M. Koczon | F | - | 5 years | |
| Douglas L. Cole | M | 77 | 13 years | |
| Karen Potts | M | 61 | 3 years | |
| Frank Torti | M | 45 | - | |
| Jeffrey Brill | M | - |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 12 years |
| Daniel Ripley | M | 63 | 6 years | |
| Jay Stoudemire | M | - |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | 3 years |
| Eugene Kennedy | M | 55 | 1 years | |
| David Slack | M | 61 | 4 years | |
| Neil Abdollahian | M | 51 | 1 years | |
| Muthiah Manoharan | M | - | 13 years | |
| Jeffrey P. Hartung | M | - |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | - |
| Michael Barrett | M | 81 | - | |
| Richard K. Brown | M | 71 | - | |
| Gary J. G. Atkinson | M | 71 | 5 years | |
| Henry Skinner | M | 60 | - | |
| Jeffrey Black | M | 55 | 2 years | |
| Jennifer Giottonini Cayer | F | - | 1 years | |
| Susan Knudson | F | 60 | - | |
| Ronald C. Griffith | M | 76 | - | |
| Lisa R. Grillone | M | 74 | 10 years | |
| William R. Shanahan | M | 74 | 6 years | |
| F. Andrew Dorr | M | - | 7 years | |
| Mark K. Wedel | M | 77 | 7 years | |
| John A. McNeil | M | 59 | - | |
| Mark Bachleda | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 49 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jon T. Holmlund
- Personal Network